GENERATE BIOMEDICINES INC (GENB) competitors & alternatives
Health Care · NASDAQ
GENERATE BIOMEDICINES INC (GENB)'s top competitors and alternatives — its most similar public companies — include RECURSION PHARMACEUTICALS INC CLAS (RXRX), NURIX THERAPEUTICS INC (NRIX), Odyssey Therapeutics, Inc. (ODTX), TYRA BIOSCIENCES INC (TYRA), Aldeyra Therapeutics, Inc. (ALDX), ATAIBECKLEY INC (ATAI), REZOLUTE INC (RZLT), TREVI THERAPEUTICS INC (TRVI), ANNEXON INC (ANNX), MONOPAR THERAPEUTICS INC (MNPR), DESIGN THERAPEUTICS INC (DSGN) and CLIMB BIO INC (CLYM). These are GENERATE BIOMEDICINES INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top GENB competitors & alternatives
-
RECURSION PHARMACEUTICALS INC CLASRXRXHealth Care
Recursion is a clinical-stage TechBio company using an AI-native operating system and massive biological datasets to industrialize and accelerate the drug…
$2.98 (as of 2026-07-22) · market cap $1.6B
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
Odyssey Therapeutics, Inc.ODTXHealth Care
A clinical-stage biotechnology company developing a pipeline of novel small molecule and protein therapeutic candidates.
$18.61 (as of 2026-07-22) · market cap $865M
-
TYRA BIOSCIENCES INCTYRAHealth Care
Tyra Biosciences is a clinical-stage biotech company developing precision small-molecule inhibitors to overcome drug resistance in cancer, particularly…
$30.59 (as of 2026-07-22) · market cap $1.8B
-
Aldeyra Therapeutics, Inc.ALDXHealth Care
Aldeyra is a clinical-stage biotech pursuing FDA approval of reproxalap, an aldehyde dehydrogenase activator for ophthalmologic inflammation, dependent on…
$1.70 (as of 2026-07-22) · market cap $106M
-
ATAIBECKLEY INCATAIHealth Care
A clinical-stage biotechnology company dedicated to developing innovative mental health therapies through a diverse pipeline of neuropsychiatric treatments.
$7.18 (as of 2026-07-22) · market cap $2.7B
-
REZOLUTE INCRZLTHealth Care
Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases.
$5.00 (as of 2026-07-22) · market cap $481M
-
TREVI THERAPEUTICS INCTRVIHealth Care
Trevi Therapeutics is a clinical-stage biotech developing Haduvio, an oral, non-scheduled dual-action opioid receptor drug, to treat chronic cough associated…
$17.36 (as of 2026-07-22) · market cap $2.5B
-
ANNEXON INCANNXHealth Care
Annexon is a clinical-stage biotechnology company developing C1q-inhibitor therapies to treat neurodegenerative and autoimmune diseases driven by the classical…
$5.23 (as of 2026-07-22) · market cap $857M
-
MONOPAR THERAPEUTICS INCMNPRHealth Care
Monopar Therapeutics is a clinical-stage biopharmaceutical firm focused on developing innovative radiopharmaceuticals for cancer and specialized treatments for…
$112.48 (as of 2026-07-22) · market cap $752M
-
DESIGN THERAPEUTICS INCDSGNHealth Care
A clinical-stage biotechnology company pioneering a novel class of small-molecule GeneTAC therapeutics to treat serious genetic diseases by modulating gene…
$11.78 (as of 2026-07-22) · market cap $736M
-
CLIMB BIO INCCLYMHealth Care
Clinical-stage biotech developing budoprutug, an anti-CD19 monoclonal antibody for B-cell depletion in autoimmune diseases including membranous nephropathy and…
$12.58 (as of 2026-07-22) · market cap $720M
Not quite? Describe exactly what you want →
Peers are GENERATE BIOMEDICINES INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: GENERATE BIOMEDICINES INC (GENB).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.